Merck to Acquire Silence Therapeutics for $1.3 Billion, Strengthening Rare Disease Platform
On Oct. 19, 2026, Merck announced it it has entered into a definitive agreement to acquire Silence Therapeutics,…
-
-
Arrowhead Pharma Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
On Nov. 18, 2025, Arrowhead Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO…
